Lilly presents 2nd-qrt results amid Alzheimer's focus

3 August 2021

US drugmaker Eli Lilly (NYSE: LLY) saw its revenue rise by 23% in the second quarter of 2021, which amounts to a 12% jump when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development.

The $6.74 billion total is marginally better than the $6.6 billion expected by analysts, while Lilly’s adjusted second-quarter profit of $1.87 a share missed Wall Street estimates by $0.02.

Profits this year are now predicted to come in around a midpoint of about $6.83 a share, instead of the previously guided midpoint of $7.13. The adjusted midpoint forecast is unchanged, at $7.90 a share.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK